ARK Genomic Revolution ETF (BATS:ARKG) Position Trimmed by Kovack Advisors Inc.

Kovack Advisors Inc. trimmed its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 7.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,109 shares of the company’s stock after selling 1,023 shares during the period. Kovack Advisors Inc.’s holdings in ARK Genomic Revolution ETF were worth $310,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Cetera Investment Advisers boosted its position in ARK Genomic Revolution ETF by 290.7% during the 1st quarter. Cetera Investment Advisers now owns 140,897 shares of the company’s stock valued at $4,052,000 after purchasing an additional 104,831 shares during the period. Main Management ETF Advisors LLC lifted its stake in ARK Genomic Revolution ETF by 2.3% in the second quarter. Main Management ETF Advisors LLC now owns 2,754,610 shares of the company’s stock valued at $64,678,000 after buying an additional 62,470 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in shares of ARK Genomic Revolution ETF by 901.5% during the second quarter. Mercer Global Advisors Inc. ADV now owns 28,943 shares of the company’s stock valued at $680,000 after acquiring an additional 26,053 shares during the period. Headlands Technologies LLC grew its position in shares of ARK Genomic Revolution ETF by 5,878.2% during the second quarter. Headlands Technologies LLC now owns 21,163 shares of the company’s stock worth $497,000 after acquiring an additional 20,809 shares during the last quarter. Finally, Prudential PLC increased its holdings in shares of ARK Genomic Revolution ETF by 15.0% in the 2nd quarter. Prudential PLC now owns 140,170 shares of the company’s stock worth $3,326,000 after acquiring an additional 18,300 shares during the period.

ARK Genomic Revolution ETF Stock Performance

Shares of BATS:ARKG opened at $22.66 on Friday. The firm has a fifty day moving average price of $24.88 and a 200-day moving average price of $25.15.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.